CTIS2023-506265-65-00招募中1 期
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
撤回
不适用
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or FusionsLocalized Bladder CancerNon-Muscle-Invasive or Muscle-Invasive Bladder Cancer10038363NL-OMON53522Janssen-Cilag20
进行中（未招募）
1 期
Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerNCT05316155Janssen Research & Development, LLC235
进行中（未招募）
1 期
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerUrinary Bladder NeoplasmsReceptors, Fibroblast Growth FactorNCT05567185Janssen Pharmaceutical K.K.5
已完成
不适用
Phase I/IIa study of intravesical administration of 2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta T cells in patients with non-invasive bladder cancer.on-invasive bladder cancerJPRN-UMIN000010942Tokyo Women's Medical University12
Unknown
3 期
A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab inParticipants with Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations.CTRI/2018/07/014718Janssen Research Development LLC